DANIPHARM A/S: Financial statements 2025
CVR: 12335040
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
DANIPHARM A/S (CVR 12335040) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 37,586,751 and a net result of DKK 13,717,304 compared with DKK 5,113,647 the year before. That is an increase of 10.3% compared with the year before. Equity in the 2025 report amounted to DKK 60,280,949. The solvency ratio was 53.3%. The company had 28 employees in the financial year.
- Gross Profit
- DKK 37,586,751
- Profit/Loss
- DKK 13,717,304
- Equity
- DKK 60,280,949
- Total Assets
- DKK 112,992,624
- Employees
- 28
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 37.6 mio. | 13.7 mio. | 60.3 mio. | 28 |
| 2024 | - | 34.1 mio. | 5.1 mio. | 46.6 mio. | 26 |
| 2023 | - | 35.2 mio. | 5.4 mio. | 41.4 mio. | 28 |
| 2022 | - | 34.9 mio. | 8.2 mio. | 36.1 mio. | 26 |
| 2021 | - | 29.4 mio. | 2.9 mio. | 29.9 mio. | 25 |
Official annual report
How creditworthy is DANIPHARM A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout DANIPHARM A/S
DANIPHARM A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1988. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The management consists of Peter Rørvig. The board consists of Niels Ulrik Heine (chair), Helle Rørvig and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. The company has 24 employees (2018). In 2025, the company reported a gross profit of DKK 37,586,751 and a net result of DKK 13,717,304 compared with DKK 5,113,647 the year before. Equity in the 2025 report amounted to DKK 60,280,949.